Reuters logo
BRIEF-Impax to review strategic alternatives for Taiwan manufacturing site
2017年5月10日 / 早上7点10分 / 6 个月前

BRIEF-Impax to review strategic alternatives for Taiwan manufacturing site

May 10 (Reuters) - Impax Laboratories Inc

* Impax reports first quarter 2017 financial results

* Q1 adjusted earnings per share $0.11

* Q1 gaap loss per share $1.37

* Q1 revenue $184.4 million versus i/b/e/s view $191.2 million

* Q1 earnings per share view $0.13 -- Thomson Reuters I/B/E/S

* Announces plans to consolidate manufacturing, packaging and generic research and development operations

* Impax says realignment expected to improve manufacturing and generic research and development efficiency, and increase annual cost savings target to approximately $130 million

* Sees fy 2017 adjusted gross margins as a percent of total revenue are expected to be approximately 47% to 49%

* Sees 2017 capital expenditures of approximately $25 million to $30 million

* Sees full year 2017 adjusted net income per share of $0.55 to $0.70

* Reviewing strategic alternatives for company’s taiwan manufacturing site including a sale of facility or in alternative, a closure of facility

* Rationalizing generic portfolio to eliminate low-value products and streamline operations

* Sees fy 2017 adjusted interest expense of approximately $28 million (previously $30 million)

* Says will incur one-time cash charges of up to approximately $65.0 million to fully achieve these new initiatives

* Impax says actions to produce annual cost savings of approximately $85.0 million, with a limited amount of savings in 2017

* Impax says consolidating all of generic research and development, U.S. Manufacturing and packing operations to its Hayward, CA facility Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below